Figure 1From: Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trialsCardiovascular risk factors and progression of renal dysfunction. *Diabetes, dyslipidemia, hypertension, obesity and metabolic syndrome. CV, cardiovascular Adapted from Chade AR, et al. Hypertension 2005;45:1042–1049.Back to article page